Designing the next-generation clinical care pathway for Alzheimer’s disease

Hampel, Harald; Au, Rhoda; Mattke, Soeren; Flier, Wiesje M. van der; Aisen, Paul S.; Apostolova, Liana G.; Chen, Christopher; Cho, Min; Santi, Susan De; Gao, Peng; Iwata, Atsushi; Kurzman, Ricky; Saykin, Andrew J.; Teipel, Stefan J.; Vellas, Bruno; Vergallo, Andrea; Wang, Huali; Cummings, Jeffrey L.

doi:10.1038/s43587-022-00269-x

Cited by 72 publications

(65 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that hearing loss is associated with cognitive decline and dementia, it may be increasingly important for hearing healthcare professionals to communicate with other practitioners who work with persons with dementia and other cognitive impairments to assure a person’s hearing acuity is considered in advance of doing any cognitive assessments. Currently, there is very little hearing screening, nor diagnosis and treatment of hearing loss in advance of cognitive services [ 44 ]. However, the incorporation of routine audiology screening in memory services may be beneficial.…”

Section: Associations Between Hearing and Healthmentioning

confidence: 99%

New horizons in holistic, person-centred health promotion for hearing healthcare

Maidment

Wallhagen²,

Dowd

et al. 2023

Age and Ageing

View full text Add to dashboard Cite

Over the course of a lifetime, the risk of experiencing multiple chronic conditions (multimorbidity) increases, necessitating complex healthcare regimens. Healthcare that manages these requirements in an integrated way has been shown to be more effective than services that address specific diseases individually. One such chronic condition that often accompanies ageing is hearing loss and related symptoms, such as tinnitus. Hearing loss is not only highly prevalent in older adults but is also a leading cause of disability. Accumulating evidence demonstrates an interplay between auditory function and other aspects of health. For example, poorer cardiometabolic health profiles have been shown to increase the risk of hearing loss, which has been attributed to microvascular disruptions and neural degeneration. Additionally, hearing loss itself is associated with significantly increased odds of falling and is a potentially modifiable risk factor for cognitive decline and dementia. Such evidence warrants consideration of new possibilities—a new horizon—for hearing care to develop a holistic, person-centred approach that promotes the overall health and wellbeing of the individual, as well as for audiology to be part of an interdisciplinary healthcare service. To achieve this holistic goal, audiologists and other hearing healthcare professionals should be aware of the range of conditions associated with hearing loss and be ready to make health promoting recommendations and referrals to the appropriate health practitioners. Likewise, healthcare professionals not trained in audiology should be mindful of their patients’ hearing status, screening for hearing loss or referring them to a hearing specialist as required.

show abstract

Section: Associations Between Hearing and Healthmentioning

confidence: 99%

New horizons in holistic, person-centred health promotion for hearing healthcare

Maidment

Wallhagen²,

Dowd

et al. 2023

Age and Ageing

View full text Add to dashboard Cite

show abstract

“… 35 The emerging treatments will require urgent development of a global framework and close collaboration with all stakeholders including the patients, specialists, the pharmaceutical industry, regulators and payors to collectively address these issues. 36 …”

Section: Discussionmentioning

confidence: 99%

The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

Tayeb

Khallaf

Muayqil

et al. 2023

NSJ

View full text Add to dashboard Cite

Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources,

show abstract

“…Anti-amyloid MABs currently under review and meeting the traditional requirements for approval based on clinical evidence of the benefit of slowing cognitive and functional decline must be reimbursed to become generally accessible. These transformative therapies require changes in health care policy, payment strategies, mechanisms to identify patients who can benefit from therapy, and processes to administer and monitor treatment [52].…”

Section: Payers and Health Costs For Older Individualsmentioning

confidence: 99%

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics

Cummings

2023

Drugs

Self Cite

View full text Add to dashboard Cite

Two anti-amyloid monoclonal antibodies (MABs)-lecanemab (Leqembi ® ) and aducanumab (Aduhelm ® )-have been approved in the USA for the treatment of Alzheimer's disease (AD). Anti-amyloid monoclonal antibodies are the first disease-modifying therapies for AD that achieve slowing of clinical decline by intervening in the basic biological processes of the disease. These are breakthrough agents that can slow the inevitable progression of AD into more severe cognitive impairment. The results of trials of anti-amyloid MABs support the amyloid hypothesis and amyloid as a target for AD drug development. The success of MABs reflects a relentless application of neuroscience knowledge to solving major challenges facing humankind. The success of these transformative agents will foster the development of more anti-amyloid MABs, other types of anti-amyloid therapies, treatments of other targets of AD biology, and new approaches to therapies for an array of neurodegenerative disorders. Monoclonal antibodies have side effects and, during the period of treatment initiation, patients must be closely monitored for the occurrence of amyloid-related imaging abnormalities (ARIA) and infusion reactions. A successful first step in the development of disease-modifying therapy for AD defines desirable features for the next phase of therapeutic development including less frequent ARIA, more convenient administration, and greater efficacy. Unprecedented agents make new demands on patients and care partners, clinicians, payers, and health care systems. Collaboration among stakeholders is essential to take advantage of the therapeutic benefits offered by these agents and to make them widely available. Monoclonal antibodies usher in a new era in AD therapy and define a new landscape of what is possible for therapeutic development for neurodegenerative disorders.

show abstract

Designing the next-generation clinical care pathway for Alzheimer’s disease

Cited by 72 publications

References 138 publications

New horizons in holistic, person-centred health promotion for hearing healthcare

New horizons in holistic, person-centred health promotion for hearing healthcare

The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics

Contact Info

Product

Resources

About